NVO News and Press, Novo Nordisk A/S

2026-03-09 06:44:09 ET The U.S. Food and Drug Administration is reportedly easing some requirements for drugmakers developing copycat versions of costly biologic medications in a bid to bring more competition to the market and lower costs. The agency plans to reduce the need f...

2026-03-09 05:41:31 ET More on related stocks: United Airlines: Rare Quality At A Peer-Group Discount Southwest Airlines: The Gate Has Closed For Value Investors American Airlines: Riskiest Legacy U.S. Airline Stock, Avoid Hims & Hers stock jumps on poten...

2026-03-09 04:22:56 ET More on Hims & Hers Health, Novo Nordisk A/S CagriSema Incident: The Surprise Winner And What It Means For The Novo-Lilly Rivalry Hims & Hers Health: Leaving GLP-1s Behind Pricing Pressure And Panic: What The Market May Be Missing In No...

2026-03-08 14:50:00 ET The weight-loss market has become one of the most active therapeutic areas in the pharmaceutical industry over the past few years. And based on analyst projections, it will continue growing at a good clip for the foreseeable future. Plenty of drugmakers are lookin...

2026-03-08 13:59:23 ET Listen below or on the go via Apple Podcasts and Spotify Oil rally expected to continue amid disruptions and shutdown fears. (0:17) February core CPI seen up slightly. (1:28) Oracle earnings will test hyperscaler AI capex demand outlook ...

2026-03-07 10:50:00 ET Things are going from bad to worse for Novo Nordisk (NYSE: NVO) . The Denmark-based drugmaker had already seen its blockbuster weight loss medicine, Wegovy, lose ground to Eli Lilly 's (NYSE: LLY) Zepbound in this fast-growing market. But Novo Nordisk ...

2026-03-07 09:20:50 ET More on Incyte, Novo Nordisk, etc. CagriSema Incident: The Surprise Winner And What It Means For The Novo-Lilly Rivalry Pricing Pressure And Panic: What The Market May Be Missing In Novo Nordisk Incyte Corporation (INCY) Presents at TD Cowen 46...

2026-03-07 08:19:03 ET More on Hims & Hers Health, Novo Nordisk CagriSema Incident: The Surprise Winner And What It Means For The Novo-Lilly Rivalry Hims & Hers Health: Leaving GLP-1s Behind Pricing Pressure And Panic: What The Market May Be Missing In Novo N...

2026-03-07 07:41:45 ET More on Pfizer, Johnson & Johnson, etc. Pfizer: Obesity Hype And Vaccine Policy Shocks The Sun Will Shine On Moderna Again - Initiating With A Buy Why Moderna's $950M Patent Bill Is A Small Price For Pipeline Freedom J&J subsidi...

2026-03-06 18:25:00 ET Is Novo Nordisk (NYSE: NVO) a bargain or a value trap as it battles Eli Lilly (NYSE: LLY) for GLP‑1 leadership, execution credibility, and premium growth? Watch the video below to see how investors might navigate this high‑stakes rivalry....